BMC Pharmacology and Toxicology is 1 and we'll see you at EUROTOX2013 to celebrate!

This month BMC Pharmacology and Toxicology reaches the milestone of one year since its grand entrance into the BMC series following the merger of its predecessors BMC Clinical Pharmacology and BMC Pharmacology, and the expansion of the new journal’s scope to include the field of Toxicology. We would like to take this opportunity to thank all of those who have contributed to the success of the journal this year including our authors, editorial board members, reviewers and all our other collaborators.

Amongst the many gifts the journal has received this year, we are pleased to annouce that BMC Pharmacology and Toxicology is currently being tracked for an impact factor (due in 2015). There are many reasons to celebrate this great achievement and a very productive year in existence. To mark this special occasion we are pleased to publish the third in our series of Question and Answer articles with our Section Editors. In this latest instalment, our esteemed Section Editor for ‘Basic Pharmacology’ David H Farb shares their insights on current developments in the field and their aspirations for the future of the journal . You can read about these issues and more here.

We are also pleased to announce that representatives from the BMC Pharmacology and Toxicology editorial team will be attending the upcoming EUROTOX2013 meeting in Interlaken, Switzerland and would be delighted to discuss all things Toxicology, open access or otherwise with you. Please don’t hesitate to contact the Executive Editor Christopher Morrey or the Journal Development Manager Genevieve Horne in advance of the meeting. We are looking forward to the exciting programme that is in store for us and would be very happy to meet you there.


View the latest posts on the BMC Series blog homepage